HCW Biologics Inc.
NASDAQ:HCWB
0.3424 (USD) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.426 | 0.619 | 1.127 | 1.324 | 0.853 | 0.623 | 0.042 | 1.342 | 1.809 | 0.454 | 3.118 | 0 | 0 | 0 | 0 | 4.1 | 0 | 0 | 0 |
| Cost of Revenue
| 0.341 | 0.438 | 0.755 | 1.346 | 0.678 | 0.502 | 0.029 | 1.073 | 1.447 | 0.287 | 1.328 | 0.096 | 0.124 | 0.165 | 0.159 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.085 | 0.18 | 0.371 | -0.022 | 0.175 | 0.12 | 0.013 | 0.268 | 0.362 | 0.167 | 1.789 | -0.096 | -0.124 | -0.165 | -0.159 | 4.1 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.2 | 0.292 | 0.329 | -0.017 | 0.205 | 0.193 | 0.299 | 0.2 | 0.2 | 0.367 | 0.574 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 1.187 | 2.029 | 1.947 | 2.136 | 1.667 | 1.617 | 2.256 | 2.93 | 2.649 | 1.97 | 1.79 | 1.483 | 2.687 | 1.673 | 2.33 | 1.409 | 2.099 | 2.069 | 1.678 |
| General & Administrative Expenses
| 2.589 | 1.594 | 5.918 | 3.556 | 3.522 | 2.949 | 3.117 | 3.006 | 1.701 | 1.691 | 1.845 | 1.583 | 1.36 | 1.017 | 1.016 | 0.569 | 0.553 | 0.655 | 0.659 |
| Selling & Marketing Expenses
| -0.069 | -0.067 | -0.067 | 5.054 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 2.519 | 11.921 | 5.918 | 8.61 | 3.522 | 2.949 | 3.117 | 3.006 | 1.701 | 1.691 | 1.845 | 1.583 | 1.36 | 1.017 | 1.016 | 0.569 | 0.553 | 0.655 | 0.659 |
| Other Expenses
| 0.069 | 1.367 | 0.026 | 0.086 | 0.235 | 0.302 | 0.383 | -0.084 | 0 | 0.017 | 0.036 | -0.163 | 0.045 | 0.061 | 0.067 | 0.06 | 0.057 | 0.057 | 0.059 |
| Operating Expenses
| 3.776 | 15.316 | 7.865 | 10.746 | 5.253 | 4.631 | 5.373 | 5.936 | 4.381 | 3.678 | 3.67 | 3.113 | 4.092 | 2.751 | 3.412 | 2.039 | 2.709 | 2.78 | 2.397 |
| Operating Income
| -3.69 | -15.136 | -7.494 | -10.768 | -5.078 | -4.511 | -5.361 | -5.667 | -4.02 | -3.511 | -1.881 | -3.113 | -4.092 | -2.751 | -3.412 | 2.061 | -2.709 | -2.78 | -2.397 |
| Operating Income Ratio
| -8.654 | -24.458 | -6.651 | -8.133 | -5.952 | -7.242 | -127.989 | -4.224 | -2.222 | -7.734 | -0.603 | 0 | 0 | 0 | 0 | 0.503 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.212 | -0.144 | 0.026 | 0.088 | 0.139 | 0.206 | 0.29 | 0.248 | 0.105 | 0.001 | -0.176 | -0.061 | -0.003 | 0.001 | 0.568 | -0 | -0 | 0.002 | 0.021 |
| Income Before Tax
| -3.902 | -15.28 | -7.468 | -10.681 | -4.939 | -4.304 | -5.071 | -5.419 | -3.914 | -3.511 | -2.057 | -3.173 | -4.095 | -2.75 | -2.844 | 2.061 | -2.709 | -2.778 | -2.376 |
| Income Before Tax Ratio
| -9.151 | -24.691 | -6.628 | -8.067 | -5.789 | -6.911 | -121.068 | -4.039 | -2.164 | -7.733 | -0.66 | 0 | 0 | 0 | 0 | 0.503 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0 | -0.531 | 0.33 | 0.397 | -0.196 | -0.073 | 0 | -0.001 | 0.176 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -3.902 | -15.28 | -7.468 | -10.681 | -4.939 | -4.304 | -4.874 | -5.346 | -3.914 | -3.51 | -2.234 | -3.173 | -4.095 | -2.75 | -2.844 | 2.061 | -2.709 | -2.778 | -2.376 |
| Net Income Ratio
| -9.151 | -24.691 | -6.628 | -8.067 | -5.789 | -6.911 | -116.378 | -3.985 | -2.164 | -7.731 | -0.716 | 0 | 0 | 0 | 0 | 0.503 | 0 | 0 | 0 |
| EPS
| -0.1 | -0.4 | -0.2 | -0.3 | -0.14 | -0.12 | -0.14 | -0.15 | -0.11 | -0.098 | -0.062 | -0.11 | -0.14 | -0.08 | -0.083 | 0.072 | -0.095 | -0.097 | -0.083 |
| EPS Diluted
| -0.1 | -0.4 | -0.2 | -0.3 | -0.14 | -0.12 | -0.14 | -0.15 | -0.11 | -0.098 | -0.062 | -0.11 | -0.14 | -0.08 | -0.083 | 0.072 | -0.095 | -0.097 | -0.083 |
| EBITDA
| -3.55 | -14.991 | -7.225 | -10.406 | -4.566 | -3.925 | -4.678 | -5.286 | -3.75 | -3.361 | -1.914 | -3.017 | -3.97 | -2.596 | -3.253 | 2.202 | -2.582 | -2.622 | -2.249 |
| EBITDA Ratio
| -8.326 | -24.223 | -6.435 | -7.926 | -5.352 | -6.301 | -118.837 | -4.224 | -2.131 | -7.404 | -0.557 | 0 | 0 | 0 | 0 | 0.543 | 0 | 0 | 0 |